Paz Vellanki: Moderating a Panel on MIDD and AI in Dose Selection at Friends of Cancer Research Meeting
Paz Vellanki / LinkedIn

Paz Vellanki: Moderating a Panel on MIDD and AI in Dose Selection at Friends of Cancer Research Meeting

Paz Vellanki, Vice President Clinical Development at Precision for Medicine, shared on LinkedIn:

“Evaluating multiple doses in oncology requires time and resources, and the decisions affect patients well beyond the clinical trial.

At the Friends of Cancer Research Annual Meeting, I moderated a panel on how model-informed drug development (MIDD) and AI can inform dose selection while keeping the goals of FDA’s Project Optimus in view.

For some dosing questions, modeling can help teams make better use of the data they already have and may reduce the need for additional clinical testing. Sponsors raised a practical concern: what would FDA need to see before relying on those analyses to support dose selection?

FDA’s MIDD Paired Meeting Program gives sponsors a way to discuss a proposed approach with the agency early. Even with encouraging feedback, teams can be hesitant to move forward.

I’d like to see both FDA and sponsors continue to share examples of where modeling has helped with dosage selection and lessons learned. Those experiences can help other teams decide when to bring a modeling proposal to FDA and what evidence to prepare. Transparency will be key for future successes with MIDD.

I appreciated Eva A. May bringing the patient perspective to our panel. Patient advocates can help define what tolerability means in practice, including which side effects patients are willing to live with over the course of treatment. That perspective belongs in dose selection. We want patients to get access to safe, effective, and tolerable therapies as soon as the evidence supports it.

Thank you to Friends of Cancer Research for bringing FDA, industry, researchers, and patient advocates together for this discussion. I greatly appreciated the expert insights provided by the panelists and MIDD working group!”

Paz Vellanki

About Friends of Cancer Research Annual Meeting

The Friends of Cancer Research (Friends) Annual Meeting is a forum held each year since 2007 that addresses critical issues in the development and regulation of novel oncology therapies. The 19th Annual Meeting took place on November 10, 2026, bringing together leaders across federal health and regulatory agencies, academic research, industry, and patient advocacy organizations to advance unique, evidence-based solutions to current challenges in drug development.

Leading up to the event each year, Friends convenes multi-stakeholder working groups across these sectors to develop collaborative white papers that identify key obstacles in oncology drug development and propose actionable solutions. During the Annual Meeting itself, expert panels examine the findings of those white papers and outline tangible next steps to drive progress across oncology research, regulatory policy, and patient advocacy.

In the 2026 Meeting, the discussions focused on modernizing early-phase oncology drug development through quantitative and risk-based methods, covering topics such as:

  • Risk-based nonclinical strategies,
  • Fit-for-purpose expectations for first-in-human studies,
  • The use of model-informed drug development (MIDD) and AI: patient tolerability perspectives to guide dose optimization.

The 2027 Annual Meeting is scheduled for November 2, 2027.

You can also read: Paz Vellanki։ Exploring Incorporating Model-Informed Drug Development and AI to Optimize Oncology Dosing